532482 Share Price Performance
₹573.50
-16.20 (-2.75%)
18.1% undervalued intrinsic discount
₹700.00
Fair Value
Price ₹573.50
AnalystHighTarget ₹700.00
AnalystLowTarget ₹480.00
AnalystConsensusTarget ₹632.14
Fair Value₹700.00
Share Pricen/a
Granules India Limited Stock Price
- 3 Narratives written by author
- 1 Comments on narratives written by author
- 27 Fair Values set on narratives written by author
532482 Community Narratives
AN
Fair Value ₹700 18.1% undervalued intrinsic discount
Expanding API Capacity And Aging Global Population Will Fuel Opportunity
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
Fair Value ₹480 19.5% overvalued intrinsic discount
Peptide CDMO Overcapacity And Debt Will Undermine Performance
0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
Fair Value ₹632.14 9.3% undervalued intrinsic discount
FDA Remediation And Genome Valley Ramp-Up Will Unlock Capacity
0users have liked this narrative
1users have commented on this narrative
20users have followed this narrative
FDA Remediation And Genome Valley Ramp-Up Will Unlock Capacity
Key Takeaways Expansion into peptide therapeutics and CDMO segments enhances diversification and margin potential in high-growth global markets. Increased manufacturing capacity, regulatory filings, and strategic focus on exports strengthen revenue visibility and long-term operational resilience.Read more
65
users have viewed this narrative0users have liked this narrative
1users have commented on this narrative
20users have followed this narrative
AN
₹632.14
9.3% undervalued intrinsic discount
AnalystConsensusTarget's Fair Value
Revenue
14.45% p.a.
Profit Margin
13.29%
Future PE
22.83x
Price in 2028
₹904
Expanding API Capacity And Aging Global Population Will Fuel Opportunity
Key Takeaways Aggressive expansion into high-value generics, oncology, peptides, and CDMO positions Granules India for sustained revenue and margin growth beyond market forecasts. Strong ESG credentials, vertically integrated manufacturing, and strategic acquisitions enable the company to capture global demand and secure premium long-term contracts.Read more
12
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
₹700
18.1% undervalued intrinsic discount
AnalystHighTarget's Fair Value
Revenue
17.55% p.a.
Profit Margin
12.96%
Future PE
25.64x
Price in 2028
₹1k
Peptide CDMO Overcapacity And Debt Will Undermine Performance
Key Takeaways Expansion into CDMO and new therapeutics is straining profitability due to overcapacity, competition, and high capital needs amid long gestation periods. Overreliance on key generics, increasing regulatory costs, and export headwinds may weaken growth, suppress margins, and heighten financial risks.Read more
5
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
AN
₹480
19.5% overvalued intrinsic discount
AnalystLowTarget's Fair Value
Revenue
15.31% p.a.
Profit Margin
13.15%
Future PE
18.37x
Price in 2028
₹686.01
Trending Discussion
Recently Updated Narratives
AN
532482: Upcoming German Acquisition And US Compliance Will Shape Balanced Outlook
Fair Value: ₹632.14 9.3% undervalued intrinsic discount
20 followersusers have followed this narrative
1 commentusers have commented on this narrative
0 likesusers have liked this narrative
AN
Peptide CDMO Overcapacity And Debt Will Undermine Performance
Fair Value: ₹480 19.5% overvalued intrinsic discount
0 followersusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
Expanding API Capacity And Aging Global Population Will Fuel Opportunity
Fair Value: ₹700 18.1% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Excellent balance sheet with reasonable growth potential and pays a dividend.
0 Risks
3 Rewards
Granules India Limited Key Details
Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
- 21.13
- 61.29%
- 10.59%
- 41.1%
About 532482
- Founded
- 1984
- Employees
- 4066
- CEO
- WebsiteView website
Granules India Limited manufactures and sells active pharmaceutical ingredients (APIs), pharmaceutical formulation intermediates, and finished dosages (FDs) in India and internationally. It offers paracetamol, metformin, guaifenesin, and methocarbamol, as well as prescription and over-the-counter products. The company also develops and manufactures tablets, capsules, press fits, oral solutions, suspensions, and powder for oral solutions. In addition, it provides development and manufacturing solutions for peptides, peptide fragments, and amino acid derivatives. The company offers its products in various therapeutic categories, including antiretroviral, anti-depressant, antihistamine, anti-diabetic, anti-cancer, multiple sclerosis, anti-thrombocytopenia, anti-ulcer, anti-convulsant, mucolytic/expectorant, anti-hypertensive, muscle relaxant, NSAIDs, anti-fibrotic, and anti-microbial, as well as anti-arrhythmic, CNS stimulant, anti-diarrheal, antihypertensive, uterine stimulant, chelating agent, mineral supplements, CNS depressant, PDE inhibitor, antispasmodic, and anti-viral. Granules India Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
